Angioplasty or medical therapy immediately after heart attack?

September 12, 2002

Authors of a study in this week's issue of THE LANCET suggest that there is no difference in treatment outcome of pre-hospital medical therapy with anti-clotting drugs or emergency angioplasty after severe heart attack.

Although the use of anti-clotting drugs before hospital admission (prehospital fibrinolysis) and primary angioplasty (widening of the coronary arteries with balloon inflation) provide a clinical benefit over the use of anti-clotting drugs given to patients in hospital, these two strategies for the treatment of severe heart attack have not been directly compared.

Eric Bonnefoy and colleagues from University Hospital, Lyon, France, did a randomised multicentre trial of 840 patients who had experienced a severe heart attack; usually this had occurred at home or at work. Patients were randomly allocated to receive pre-hospital fibrinolysis (with the anti-clotting drug alteplase), or were given emergency angioplasty on arrival at hospital. All patients were transferred to a centre with access to emergency angioplasty. Patients assigned to pre-hospital fibrinolysis were scheduled to undergo complementary emergency angioplasty ("rescue") if the initial treatment was suspected to have failed.

There were no statistically significant differences between the two treatment strategies in the main outcome measures of the study (death, recurrence of heart attack, or disabling stroke, within one month of treatment); although there were trends suggesting increased risk of heart-attack recurrence and stroke among patients given fibrinolytic therapy. As expected, it took longer to administer angioplasty (just over three hours on average) than fibrinolytic therapy (two hours). Around a quarter of patients randomised to receive fibrinolytic therapy underwent subsequent emergency "rescue" angioplasty.
-end-
Despite no difference in mortality outcome in Bonnefoy and colleagues' study, Greg Stone from Lenox Hill Heart and Vascular Institute, New York, USA, in an accompanying Commentary (p 814) asserts that, taken together, all the available evidence is a 'wake-up call' for early intervention. He concludes: "...the best therapy for most patients with evolving AMI [acute myocardial infarction] should no longer be debated: administer antiplatelet therapy (aspirin, a thienopyridine and possibly abciximab), withhold thrombolytic therapy, and transfer the patient for primary PTCA [angioplasty], regardless of whether the nearest catheterisation suite is three floors or 3 h away. To do less should no longer be considered standard care. Strong words, yes, but it is time for a wake-up call."

Contact:
P Touboul,
Hopital Cardiovasculaire et Pneumologique Louis Pradel, CHU de Lyon,
BP Lyon Monchat,
69394 Lyon, Cedex 03, France;
T) 33-4-72-35-75-49;
F) 33-4-72-35-73-41;
E) paul.touboul@chu-lyon.fr

Dr Greg Stone, Lenox Hill Heart and Vascular Institute,
Cardiovascular Research Foundation, New York City, NY 10022, USA;
E) gstone@crf.org

Lancet

Related Heart Attack Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

Muscle protein abundant in the heart plays key role in blood clotting during heart attack
A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

New target identified for repairing the heart after heart attack
An immune cell is shown for the first time to be involved in creating the scar that repairs the heart after damage.

Heart cells respond to heart attack and increase the chance of survival
The heart of humans and mice does not completely recover after a heart attack.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Mount Sinai discovers placental stem cells that can regenerate heart after heart attack
Study identifies new stem cell type that can significantly improve cardiac function.

Fixing a broken heart: Exploring new ways to heal damage after a heart attack
The days immediately following a heart attack are critical for survivors' longevity and long-term healing of tissue.

Heart patch could limit muscle damage in heart attack aftermath
Guided by computer simulations, an international team of researchers has developed an adhesive patch that can provide support for damaged heart tissue, potentially reducing the stretching of heart muscle that's common after a heart attack.

How the heart sends an SOS signal to bone marrow cells after a heart attack
Exosomes are key to the SOS signal that the heart muscle sends out after a heart attack.

Read More: Heart Attack News and Heart Attack Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.